Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Human immunodeficiency virus–seronegative men aged 15–22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP in participants aged 15–19 years.

Clinical Trials Registration. NCT01772823 (ATN 110) and NCT01769456 (ATN 113).

Related collections

Author and article information

Journal

Journal ID (nlm-ta): Clin Infect Dis

Journal ID (iso-abbrev): Clin. Infect. Dis

Journal ID (publisher-id): cid

Title: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Publisher: Oxford University Press (US )

ISSN (Print): 1058-4838

ISSN (Electronic): 1537-6591

Publication date (Print): 15 February 2020

Publication date (Electronic): 08 June 2019

Publication date PMC-release: 08 June 2020

Volume: 70

Issue: 4

Pages: 687-691

Affiliations

[1 ] Department of Pediatrics, Medical College of Wisconsin/Children’s Hospital of Wisconsin , Milwaukee

[2 ] Department of Biostatistics, University of Alabama at Birmingham

[3 ] Department of Epidemiology, University of Alabama at Birmingham

[4 ] Westat , Rockville, Maryland

[5 ] Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora

[6 ] Department of Medicine, David Geffen School of Medicine, University of California Los Angeles

[7 ] Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development , Bethesda, Maryland

[8 ] Department of Psychiatry, Stroger Hospital of Cook County , Chicago, Illinois

[9 ] Department of Medicine, University of California at San Francisco, Zuckerberg San Francisco General Hospital

Author notes

Correspondence: P. L. Havens, Professor of Pediatrics and Epidemiology, Medical College of Wisconsin, Suite C450, 999 North 92nd Street, Milwaukee, WI 53226 ( phavens@ 123456mcw.edu ).

Article

Accession ID: PMC7319267 Pmcid ID: PMC7319267 Pmc-uid ID: 7319267 Publisher ID: ciz486

DOI: 10.1093/cid/ciz486

PMC ID: 7319267

PubMed ID: 31179503

SO-VID: 82b33218-a204-4ca5-96dc-18945a1ee647

License:

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

History

Date received : 24 January 2019

Date accepted : 06 June 2019

Date: 09 May 2019

Page count

Pages: 5

Funding

Funded by: National Institutes of Health, DOI 10.13039/100000002;

Award ID: U01 HD040533

Award ID: U01 HD040474

Funded by: Eunice Kennedy Shriver National Institute of Child Health and Human Development, DOI 10.13039/100009633;

Funded by: National Institute on Drug Abuse, DOI 10.13039/100000026;

Funded by: National Institute of Mental Health, DOI 10.13039/100000025;

Funded by: Gilead Sciences, DOI 10.13039/100005564;

Comments

Comment on this article

scite_

Cited by 8

See all cited by

- Version 1